BRD4-IN-11

• Description:

  BRD4-IN-11 is an orally active and selective BRD4 inhibitor (IC50 = 26.35 nM (BD1), IC50 = 72.81 nM (BD2) ) . BRD4-IN-11 is approximately 3- to 18-fold more potent against BRD4 than againstBRD2, BRD3, and BRDT. BRD4-IN-11 enhances H2S release and inhibits the upregulation of fibrotic markers (α-SMA and fibronectin), c-Myc, and CDC25B. BRD4-IN-11 reduces apoptosis in LO2 hepatocytes. BRD4-IN-11 significantly improves liver and lung function in a hepatopulmonary fibrosis model and can be used to study hepatopulmonary fibrosis[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; c-Myc; Epigenetic Reader Domain; Phosphatase

• Related Pathways:

  Apoptosis; Epigenetics; Metabolic Enzyme/Protease

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Inflammation/Immunology

• Smiles:

  CC1=NN=C2[C@@H](N=C(C3=C(N12)SC(C)=C3C)C4=CC=C(C=C4)Cl)CC(OC5=CC=C(C=C5)OCCCCCCOC6=CC=C(C=C6)C7=CC(SS7)=O)=O

• Molecular Formula:

  C40H37ClN4O5S3

• Molecular Weight:

  785.39

• References & Citations:

  [1]Zhu Y, et al. Design, synthesis, and biological evaluation of a dual-action agent targeting bromodomain and extraterminal domain and H2S release for the treatment of hepatic and pulmonary injury. Eur J Med Chem. 2025 Oct 15;296:117887.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  BRD4